Drug Product Science & Technology Department, Bristol-Myers Squibb Co, New Brunswick, New Jersey 08903, USA.
AAPS J. 2012 Sep;14(3):591-600. doi: 10.1208/s12248-012-9372-3. Epub 2012 May 30.
Modeling and simulation of drug dissolution and oral absorption has been increasingly used over the last decade to understand drug behavior in vivo based on the physicochemical properties of Active Pharmaceutical Ingredients (API) and dosage forms. As in silico and in vitro tools become more sophisticated and our knowledge of physiological processes has grown, model simulations can provide a valuable confluence, tying-in in vitro data with in vivo data while offering mechanistic insights into clinical performance. To a formulation scientist, this unveils not just the parameters that are predicted to significantly impact dissolution/absorption, but helps probe explanations around drug product performance and address specific in vivo mechanisms. In formulation, development, in silico dissolution-absorption modeling can be effectively used to guide: API selection (form comparison and particle size properties), influence clinical study design, assess dosage form performance, guide strategy for dosage form design, and breakdown clinically relevant conditions on dosage form performance (pH effect for patients on pH-elevating treatments, and food effect). This minireview describes examples of these applications in guiding product development including those with strategies to mitigate observed clinical exposure liability or mechanistically probe product in vivo performance attributes.
在过去十年中,基于活性药物成分 (API) 和剂型的物理化学性质,药物溶解和口服吸收的建模和模拟越来越多地用于了解体内药物行为。随着计算和体外工具变得更加复杂,我们对生理过程的了解也不断增加,模型模拟可以提供有价值的融合,将体外数据与体内数据联系起来,同时为临床性能提供机制见解。对于制剂科学家来说,这不仅揭示了预计会显著影响溶解/吸收的参数,还有助于探究药物产品性能的解释,并解决特定的体内机制问题。在制剂开发中,计算溶解-吸收模型可以有效地用于指导:API 选择(剂型比较和粒径特性)、影响临床研究设计、评估剂型性能、指导剂型设计策略以及分解剂型性能的临床相关条件(对接受升高 pH 治疗的患者的 pH 影响,以及食物影响)。这篇综述性文章介绍了这些应用在指导产品开发方面的示例,包括那些具有减轻观察到的临床暴露风险或从机制上探究产品体内性能属性的策略。